Clinical trials: LOCALLY ADVANCED RECTAL CANCER
Rectal Cancer, Liver Metastases
Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases
To investigate the feasibility of preoperative chemoradiation with oxaliplatin plus capecitabine, with or without prior induction chemotherapy in patients with locally advanced or marginally resectable rectal cancer with…
- Trial name
- NCT01643070
- Testing
- Capecitabine, Oxaliplatin, Radiotherapy
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Asan Medical Center
Colorectal Cancer
Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer
The goal of this laboratory research is to look for genes that can predict which patients will achieve a complete disappearance of their colorectal cancer after treatment like chemotherapy, radiation, or other therapy.
- Trial name
- NCT02877056
- Testing
- Endoscopy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- M.D. Anderson Cancer Center
Rectal Cancer
Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
The study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have…
- Trial name
- NCT02008656
- Testing
- Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin
- Where
- 26 sites in United States
- Volunteers
- 358 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Rectal Cancer (LARC)
To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR
To evaluate the pathological complete response rate (pCR) of intestinal flora transplantation combined with short-course radiotherapy +CAPOX+ sintilimab in neoadjuvant therapy for locally advanced rectal cancer (pMMR/MSS type)
- Trial name
- NCT07738042
- Testing
- Sintilimab, CAPOX (oxaliplatin/capecitabine), Short-course radiotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Neoplasms
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer
The purpose of this study is to determine whether 18F-FDG-PET-CT and texture analysis of MRI performed 9 weeks after Neoadjuvant Chemo-radiotherapy in patients with locally advanced rectal cancer has the ability to identify…
- Trial name
- PRENT-LARC (NCT02439086)
- Testing
- PET-CT Scan
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Colchester General Hospital
Rectal Adenocarcinoma, High-risk Locally Advanced
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
This study adopts a prospective randomized controlled design to evaluate the efficacy and safety of short-course radiotherapy followed by sequential PD-1 inhibitor and FOLFOX chemotherapy versus conventional regimens in high-risk…
- Conditions
- Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT), Immunotherapy
- Trial name
- STAR (NCT07669220)
- Testing
- Short-course Radiotherapy, SCRT, Toripalimab
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
This project intends to make a study of personalized medicine evaluation system establishment for liver cancer, gastric cancer and nasopharynx cancer to provide strong support for the development of Precision Medicine and…
- Trial name
- NCT03260179
- Testing
- AL3810
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Rectal Cancer, Total Neoadjuvant Treatment
Short-course Radiotherapy With Induction and Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer
Short-course radiotherapy followed by consolidation chemotherapy has shown a better response rate when compared to chemoradiotherapy treatment.
- Trial name
- SHORT-ICAR (NCT04674696)
- Testing
- Approach
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Locally Advanced Rectal Cancer (LARC)
A Pospective, Single-arm, Multicenter Clinical Trial Evaluating Preoperative Neoadjuvant mFOLFOX6 Chemotherapy in Combination With PD1 Monoclonal Antibody in MSS/pMMR Locally Advanced Rectal Cancer
Preoperative neoadjuvant chemoradiotherapy can induce tumor regression and reduce the risk of postoperative recurrence, serving as the standard treatment for locally advanced rectal cancer.
- Trial name
- FIRM (NCT06688786)
- Testing
- neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer
THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality for locally advanced rectal cancer (LARC), and patients achieving complete response (CR) generally have improved local control, metastasis-free…
- Conditions
- Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer, Pathological Complete Response
- Trial name
- THUNDER2 (NCT04815694)
- Testing
- RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rectal Cancer
Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer
The aims of the trial are (1) to determine the tolerability rate in the setting of a multi-centre study and (2) to determine secondary tolerability endpoints, toxicity rates and complete pathologic response rate in patients with…
- Trial name
- PROArCT (NCT01013805)
- Testing
- External Beam Radiotherapy, Oxaliplatin, Fluorouracil
- Where
- Australia
- Volunteers
- 41 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Rectal Cancer
Study of the Predictive and Prognostic Role of Pharmacogenetic and Radiogenic Variants on the Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer
In locally advanced rectal cancer the pathological complete response (pCR) to neoadjuvant chemoradiation therapy (nCRT) is associated with a favourable long-term prognosis.
- Trial name
- IGLarc (NCT06616870)
- Where
- Italy
- Volunteers
- 460 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Rectal Cancer
Preoperative Intraarterial Chemoembolization Combined With Radiotherpy in Locally Advanced Rectal Cancer
Compared to postoperative chemotherapy combined with radiotherapy, preoperative chemotherapy combined with radiotherapy shows higher sphincter preservation rate and lower local recurrence rate in locally advanced rectal cancer.
- Trial name
- PCAR (NCT03601156)
- Testing
- intraarterial chemoembolization, intravenous chemotherapy
- Where
- 3 sites in China
- Volunteers
- 204 people
- Sponsor
- Third Military Medical University
Locally Advanced Rectal Carcinoma
Preoperative, Adaptive Radiotherapy Concomitant to Chemotherapy for Rectal Adenocarcinoma (Adaptive Rectal Cancer Trial 02)
The aim of this clinical study is to increase the rate of pathological responses up to 70% by means of improved patient selection operated by a radiobiological index called ERI_TCP and by an increase in the dose of radiotherapy…
- Trial name
- NCT07580027
- Testing
- Preoperative, adaptive radiotherapy
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- IRCCS San Raffaele
Neoplasms, Breast, Neoplasms, Lung
Study of ESG401 in Adults With Solid Tumors
The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer.
- Conditions
- Neoplasms, Breast, Neoplasms, Lung, Neoplasms,Colorectal, Neoplasms, Bladder
- Trial name
- NCT04892342
- Testing
- ESG401
- Where
- 3 sites in China
- Volunteers
- 156 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
This phase II trial investigates the effect of nivolumab and ipilimumab when given together with short-course radiation therapy in treating patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT04751370
- Testing
- Computed Tomography, Ipilimumab, Magnetic Resonance Imaging
- Where
- 213 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-)
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced…
- Conditions
- Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor
- Trial name
- NCT04165772
- Testing
- TSR-042 or Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT)
- Where
- 10 sites in United States
- Volunteers
- 212 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Cancer
Conventional Versus Individual Extralvator Abdominoperineal Excision for Advanced Lower Rectal Cancer
An alternative treatment for low rectal cancer is the extralevator abdominoperineal excision (ELAPE) technique. We aim to compare the outcomes of patients undergoing conventional ELAPE versus Individual ELAPE.
- Trial name
- ELAPE (NCT02036112)
- Testing
- conventional ELAPE, Individual ELAPE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Chao Yang Hospital
Colorectal Cancer, Non-Small Cell Lung Cancer
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.
- Trial name
- NCT05954871
- Testing
- GDC-1971, Osimertinib, Cetuximab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer, Microsatellite Instability High
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with PD-1 inhibitors (Camrelizumab) plus VEGF inhibitor (Apatinib) for dMMR/MSI-H colorectal cancer staged as locally advanced (cT3-4N+/-M0…
- Trial name
- NCT04715633
- Testing
- PD-1 inhibitor plus VEGF inhibitors
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University